018680 — Seoul Pharma Co Balance Sheet
0.000.00%
- KR₩39bn
- KR₩48bn
- KR₩54bn
Annual balance sheet for Seoul Pharma Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | Annual Audited Accounts | ARS | ARS | ARS | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 15,061 | 13,820 | 11,728 | 9,664 | 7,540 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 3,238 | 4,489 | 5,040 | 5,131 | 9,465 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 25,933 | 24,814 | 26,012 | 25,609 | 32,257 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 35,476 | 34,055 | 30,676 | 31,330 | 33,855 |
Net Intangible Assets | |||||
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 65,087 | 62,250 | 62,428 | 63,305 | 71,620 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 18,447 | 28,805 | 13,891 | 20,532 | 14,141 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 36,235 | 43,292 | 27,006 | 24,741 | 31,448 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 28,852 | 18,958 | 35,422 | 38,564 | 40,172 |
Total Liabilities & Shareholders' Equity | 65,087 | 62,250 | 62,428 | 63,305 | 71,620 |
Total Common Shares Outstanding |